- Dec 16, 2013
- 1 min read

Acesion Pharma and university partner receives 14 mio DKK (2.6 mio USD) in funding from The Danish N

Acesion Pharma has, together with the Danish National Research Foundation Centre for Cardiac Arrhythmia at Copenhagen University, received a grant from The Danish National Advanced Technology Foundation. The investment is in a four year program to develop novel drugs against atrial fibrillation, and the foundation grant covers half of the total budget of 28 mio DKK.

The Danish National Advanced Technology Foundation is founded by the Danish government and has the general objective to enhance growth by supporting strategic and advanced technological priorities within the fields of research and innovation.

Recent Posts

See All

Acesion Pharma announces Nature Medicine publication of clinical results in Atrial Fibrillation

AP30663 achieved proof of mechanism with first-in-class SK channel inhibition compound in atrial fibrillation – primary endpoint met: 99.9% probability of superiority over placebo AP31969, a novel com

Acesion Pharma Closes Oversubscribed €45M Series B Financing Round

Financing co-led by new investors Canaan and Alpha Wave, and with participation by the Global BioAccess Fund and existing investor Novo Holdings Copenhagen, Denmark – Acesion Pharma (“Acesion” or “the

Acesion Pharma Announces Positive Pre-Clinical Data for AP31969

Copenhagen, Denmark – Acesion Pharma (“Acesion” or “the Company”), a biotech company pioneering first-in-class novel therapies for atrial fibrillation (“AF”), the most common cardiac arrhythmia, today